Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02896335 · ClinicalTrials.gov registry record · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
A Phase 2 study of Recurrent Brain Metastases and Progressive Brain Metastases, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT02896335: Recruiting Phase 2 study of Recurrent Brain Metastases and Progressive Brain Metastases, sponsored by Massachusetts General Hospital.
NCT02896335 is a Phase 2 study of Recurrent Brain Metastases and Progressive Brain Metastases that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02896335, a Phase 2 study of Recurrent Brain Metastases and Progressive Brain Metastases, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and Merck, pharmaceutical companies, are supporting this research study by providing the study drugs as well as funding for research activities.
Primary Outcome
Intracranial Clinical Benefit is defined by complete response (CR), partial response (PR) or stable disease (SD) in the central nervous system (CNS). The proportion of patients in Cohort 1 with response in the CNS will be presented with a two-sided, 90% confidence interval based on the method of Atkinson and Brown, which allows for the two-stage design.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Palbociclib
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-02-02 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
What NCT02896335 shows while recruiting
NCT02896335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 3 conditions, with Recurrent Brain Metastases appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02896335 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02896335 about?
NCT02896335 is a clinical study titled "Palbociclib and Pembrolizumab In Central Nervous System Metastases". This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and...
What is the current status of trial NCT02896335?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2017-02-02. Estimated completion is 2027-09-01.
What conditions does trial NCT02896335 study?
This clinical trial studies the following conditions: Recurrent Brain Metastases, Progressive Brain Metastases, Metastatic Malignant Neoplasm to Brain.
What interventions are being tested in trial NCT02896335?
The interventions under investigation include: Pembrolizumab (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT02896335?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02896335 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02896335's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
- NCT03588975 · 45 participants · Phase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI